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Abstract
Background: Suicidal ideations, suicide attempts, and fatal suicides are rare adverse drug reactions to antidepressant drugs, 
but they essentially are clinically relevant. Drawing on a larger dataset of the European drug surveillance program, the present 
naturalistic study updates a previous contribution (Stübner et al., 2010).
Methods: First an analysis of the comprehensive data collected in 81 psychiatric hospitals from 1993 to 2014 by the European 
drug surveillance program Arzneimittelsicherheit in der Psychiatrie was made. All documented single cases of suicidal 
ideations or behavior judged as adverse drug reactions to antidepressant drugs were carefully assessed as to their clinical 
features and drug prescriptions.
Results: Among 219,635 adult hospitalized patients taking antidepressant drugs under surveillance, 83 cases of suicidal 
adverse drug reactions occurred (0.04%): 44 cases of suicidal ideation, 34 attempted suicides, and 5 committed suicides 
were documented. Restlessness was present in 42 patients, ego-dystonic intrusive suicidal thoughts or urges in 39 patients, 
impulsiveness in 22 patients, and psychosis in 7 patients. Almost all adverse drug reactions occurred shortly after beginning 
antidepressant drug medication or increasing the dosage. Selective serotonin reuptake inhibitors caused a higher incidence of 
suicidal ideation and suicidal behavior as adverse drug reactions than noradrenergic and specific serotonergic antidepressants 
or tricyclic antidepressants, as did monotherapy consisting of one antidepressant drug, compared to combination treatments.
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Conclusions: The study supports the view that antidepressant drug-triggered suicidal ideation and suicidal behavior (primarily 
with selective serotonin reuptake inhibitors) are rare. Special clinical features (restlessness, ego-dystonic thoughts or urges, 
impulsiveness) may be considered as possible warning signs. A combination therapy might be preferable to antidepressant 
drug monotherapy when beginning treatment.
Keywords: antidepressants, SSRI, adverse drug reaction, suicide, drug safety
Introduction
An essential goal of prescribing medication with antidepres-
sants (ADs) is to prevent patients from attempting or committing 
suicide and to treat or avert suicidal ideation. In fact, pharma-
coepidemiological studies have shown that suicides declined as 
the prescription rate of AD increased (Möller, 2006; Brent, 2016). 
However, since 1988, enlarged and new-onset suicidal activities 
have been reported in association with antidepressant medica-
tion, first with imipramine (Damluji and Ferguson, 1988), later 
with maprotiline (Rouillon et al., 1989) and fluoxetine (Teicher 
et al., 1990). Suicidal ideations were first described as adverse 
drug reactions (ADRs) to ADs in connection with psychomotor 
activation, especially ADs with low sedative effects (Grohmann 
et al., 1993; Ströbel et al., 1994). In some cases they have been a 
consequence of drug-induced psychosis (Grohmann et al., 1993). 
Over the last 2 decades, the controversy surrounding this issue 
has focused on the role of selective serotonin reuptake inhibi-
tors (SSRIs) (Healy and Whitaker, 2003; Whittington et al., 2004, 
2005; Juurlink et al., 2006; Möller et al., 2008).
Meta-analyses of randomized controlled trials (RCTs) have 
yielded contradictory results (Baldessarini et al., 2017). Gunnell 
and colleagues stated in their meta-analysis that the effects 
of SSRIs could not be assessed because of the rarity of suicidal 
events (Gunnell et  al., 2005). Whereas one analysis of RCTs 
(Vanderburg et al., 2009) reported no effect on suicidal behav-
ior, neither for different age groups nor different types of sui-
cidal behavior, another review (Fergusson et al., 2005) described 
a 2-fold increase of fatal and nonfatal suicide attempts. A third 
study reported only weak evidence that SSRIs increased the 
risk of suicidal self-harm (Martinez et al., 2005). Another meta-
analysis found only a small risk of inducing suicidal thoughts 
and suicide attempts in groups of patients under 25  years of 
age, and this risk decreased as age increased (Stone et al., 2009). 
The most recent meta-analysis on long-term RCTs of ADs found 
an increased rate of suicide attempts during long-term treat-
ment with ADs. Nevertheless, the authors concluded that it is 
still unclear whether ADs increase the risk of suicide attempts 
(Braun et al., 2016).
In 2010 we reported data on 33 cases of suicidal ideation and 
suicidal behavior, which had been observed by the European 
drug surveillance program AMSP (Arzneimittelsicherheit in der 
Psychiatrie) and judged to be related to the administration of 
ADs (Stübner et al., 2010) over the time period of 1993 to 2008 
(see also Baldessarini, 2011 and Stübner et al., 2011).
It was found (Stübner et al., 2010) that mainly the clinical fea-
tures of restlessness, impulsiveness, and ego-dystonic thoughts 
or urges (i.e., patients experiencing suicidal thoughts and urges 
as strange to themselves) preceded drug-induced suicidal idea-
tion and suicidal behavior or accompanied it, respectively. 
A  higher incidence of suicidal ADRs was observed in patients 
who had received SSRIs or selective serotonin norepinephrine 
reuptake inhibitors (SNRIs) compared with patients receiv-
ing noradrenergic and specific serotonergic antidepressants 
(NaSSAs) or tricyclic antidepressants (TCAs). The present study 
is based on a larger database allowing more powerful analyses.
METHODS
Data from the AMSP program for Drug Safety in Psychiatry 
(Arzneimittelsicherheit in der Psychiatrie) collected from 1993 
to 2008 had already been analyzed using the same methods 
(Stübner et al., 2010). Now a follow-up analysis was made (from 
the above-mentioned AMSP data collected from 1993 until 
2014) to prove the previous findings reported on a small sample 
dataset drawn from the larger dataset.
The AMSP program was established in 1993. It was to be a 
continuous, open-end study for the assessment of severe ADRs 
to all marketed psychotropic drugs during routine treatment 
of psychiatric inpatients in Austria, Germany, and Switzerland. 
The AMSP thus replaced an earlier, similar drug surveillance 
program (Arzneimittelüberwachung in der Psychiatrie [AMÜP]; 
(Grohmann et al., 1993; Ströbel et al., 1994).
The AMSP methods were described in detail earlier (Engel 
et  al., 2004; Grohmann et  al., 2004; Grohmann et  al., 2014). In 
brief, only clinically severe ADRs are assessed. The criteria of 
the program are based on the severity of the event itself and its 
potential danger to the patient’s health. ADRs are documented 
by trained psychiatrists who contact the ward psychiatrists 
and document the ADR cases using standardized question-
naires. Age, gender, and psychiatric and somatic diagnoses are 
recorded along with a detailed description of the adverse event, 
potential risk factors, clinical measures taken because of the 
ADR, and its subsequent outcome. The psychiatric and somatic 
Significance Statement
The debate on suicidal thoughts and behavior as adverse drug reactions of treatment with antidepressants is still ongoing. 
While pharmacoepidemiological studies indicate a decline in suicides with increasing prescriptions of antidepressants, meta-
analyses of controlled trials and clinical reports suggest possible new-onset suicidality due to antidepressant treatment. A drug 
monitoring program identified 83 cases of suicidal adverse drug reactions that may be associated with antidepressant treat-
ment. The analysis allows to describe clinical features that might be considered as possible warning signs. The results show that 
antidepressant-induced suicidal thoughts and behaviors are rare and that the risk of developing suicidal adverse drug reactions 
appears to be different for various groups of antidepressants. There was a higher proportion of antidepressant monotherapy 
among patients with suicidal adverse drug reaction compared with all patients monitored.
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drug data (dosage, time course, concurrent medication), previ-
ous exposure to the imputed drugs, that is, drugs that have been 
evaluated as the suspected cause of adverse reactionstreatment 
after the adverse event, and outcome in case of rechallenge are 
also documented.
All these factors are taken into account to rate the probabil-
ity that a causal relationship between medication and adverse 
event is possible, probable, or definite according to AMSP crite-
ria. After careful discussion at case conferences, the cases are 
stored in the central surveillance database for further analysis.
Data on drug use by all patients under AMSP surveillance 
at the participating centers are regularly documented on 2 ref-
erence days per year. All drugs and their dosages are recorded 
along with age, gender, and diagnoses of the patients.
Special Procedure of this Analysis
For the present study, all cases of suicidal ideation or behavior, 
which were judged to be possibly or probably causally related 
to ADs and thus assessed to be ADRs, were extracted from the 
database covering the period from 1993 to 2014. They were then 
analyzed along with background information on demographic 
data and drug use of the patients under surveillance.
Criteria for Assessing Suicidal Ideation or Behavior 
as an ADR
Suicidal thoughts and attempts are frequently illness-related 
features of psychiatric inpatients, and it is often difficult to dif-
ferentiate between drug-related and illness-related events. As 
the course of psychiatric illness itself can never be completely 
excluded as a contributing factor, a “definite” causal relationship 
between the ADR and the drug cannot be assumed. However, in 
our assessment system, suicidal ideation or behavior is rated as 
an ADR only if it is connected with treatment-emergent symp-
toms. This allows us to judge whether the event is at least “pos-
sibly” drug related, for example, inner or motor restlessness, 
agitation, ego-dystonic thoughts or urges, psychosis, or change 
in behavior. The unexpectedness of a suicidal action alone is 
not sufficient to rate it as a drug-related event. Special symp-
toms like emergent agitation have to be observed by the staff or 
reported by the patient. In particular, the assessment of ego-dys-
tonic, suicidal impulses such as urges and thoughts experienced 
by the patients as completely strange to themselves are relevant 
and rely mostly on the concerned patient’s explicit description. 
For this reason, it is particularly difficult and often impossible to 
assess causality in fatal suicides, which are then rated as “not 
assessable.” Such cases are not included in the present study.
Classification of Substances
ADs were classified according to clinical conventions: as mono-
amine oxidase inhibitors (MAOIs), NaSSAs, SSNRIs, SSRIs, or 
TCAs. The following substances were subsumed under “other 
antidepressants” (OADs): bupropion, nefazodone, reboxetine, 
tianeptine, trazodone.
Data Evaluation
ADRs are represented in absolute numbers and incidence rates. 
The number of patients exposed to a drug (or drug group) was 
estimated on the basis of drug-use data collected on 2 reference 
days per year. ADR incidence rates are presented together with 
exact confidence intervals (Clopper and Pearson, 1934).
The effects of age, gender, diagnosis, and drugs on suicidal 
ADRs were evaluated statistically by chi-squared or Fisher’s exact 
tests. However, statistical inference was used as an exploratory 
technique, since the focus of the AMSP project is the descriptive 
presentation of ADR data, not the proof of hypotheses.
Evaluations based on the AMSP data bank have been 
approved by the Ethics Committee of the University of Munich. 
This study adhered to the Declaration of Helsinki and its later 
amendments
RESULTS
Demographic Characteristics and Data on Drug Use 
of Patients
Between 1993 and 2014, a survey was made of 447,566 patients 
receiving psychopharmacological treatment. Of these, 219,635 
patients were treated with ADs.
The use of ADs changed fundamentally over time (see sup-
plementary Fig.  S1). In 1994, 76% of the patients treated with 
ADs received TCAs. In 2000, more patients were treated with 
SSRIs (37%) than with TCAs (34%), and SSRIs remained from then 
on the subgroup most often applied, although their usage has 
somewhat declined. From 2002 onwards, NaSSAs were admin-
istered in about 27%. In 2014, SSRIs were the ADs most often 
administered (38%), followed by SNRIs (32%), NaSSAs (26%), and 
TCAs (11%). MAOIs (about 1%) were used in only rare cases. In 
2014, OADs were applied in about 20%.
A total of 83 cases of suicidal ADRs were documented dur-
ing the period 1993 to 2014: 44 cases of suicidal ideation, 34 
attempted suicides, and 5 fatal suicides. We analyzed the pos-
sible influences of demographic characteristics on the incidence 
rates of suicidal ADRs. While gender did not seem to have an 
effect, an impact was found for age and diagnosis: suicidal ADRs 
were more often seen in patients younger than 30 years (com-
pared with their share in the AMDP dataset) and less often in 
patients older than 60 years. Suicidal ADRs were also more often 
seen in diagnoses of affective disorders (ICD 10: F3) and less 
often in diagnoses of schizophrenia and related disorders (ICD 
10: F2; Table 1).
Clinical Features During ADRs and Details of 
Suicidal ADRs
From 1993 to 2014 suicidal ADRs were related to restlessness 
(52%), ego-dystonic thoughts or urges (47%), and impulsiveness 
(27%) in the majority of patients; few patients suffered from psy-
chosis (8%; more than one feature per patient possible).
Time of Onset
Most suicidal ADRs occurred shortly after beginning AD medi-
cation or increasing the dosage. Fifty-nine of the 83 ADR cases 
occurred within the first 7 days (71%), 18 cases between day 7 
and 14 (22%), and only 6 afterwards (2 had psychoses: 7%).
Subsequent Treatment and Outcome
Several treatment strategies were applied. In most of the cases, 
the imputed drugs were discontinued (n = 66, i.e., 79.5%); dosage 
was reduced in another 5 cases (6%). In 22 cases (26.5%) a trans-
fer to a ward or institution with more intensive care or another 
hospital was necessary. Additional drugs to counteract the ADR 
were administered in 34 cases (41%, mostly benzodiazepines); in 
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33 cases nonpharmacological interventions were used (mostly 
psychotherapy).
Imputed Medication
The observed numbers of ADRs during treatment with ADs were 
compared to all patients monitored while taking the imputed 
medication in the period 1993–2014.
Table 2 gives a detailed overview of the AD subgroup and sin-
gle-drug use of the patients with suicidal ADRs compared with 
all other patients surveyed by AMSP together with the results 
of the descriptive Fisher’s exact test. SSRIs were involved in the 
majority of the ADR cases (n = 47, i.e., 57%). Patients with sui-
cidal ADRs were more often treated with SSRIs compared with 
all patients on ADs (57% vs 38%) and less often with NaSSAs 
(10% vs 26%) or with TCAs (4% vs 24%). The differences were sta-
tistically significant for SSRIs, NaSSAs, and TCAs and also for the 
single substances citalopram and mirtazapine.
In 71 cases a single substance was considered to have 
caused the ADRs; in another 4 cases AD combinations were 
imputed. In 8 cases a combination of at least 1 AD and another 
drug was regarded as having provoked the ADRs: in 5 cases 
an antipsychotic drug, in the other 3 cases a tranquillizer or 
methylphenidate.
Figure 1 shows the relative frequencies of suicidal ADRs for 
the different subgroups of ADs together with their exact con-
fidence intervals. Only those cases were included in which a 
single AD had been imputed for the ADR (n = 71). Higher rates 
were observed for SSRIs compared with NASSAs and TCAs (for 
details, see the legend to  Figure 1).
The median AD dosages of the ADR patients at the onset 
of ADRs were similar or even lower than that of the total 
population.
AD monotherapy (1 AD without any psychotropic comedica-
tion) was administered in 27 of the 83 ADR cases (33%), mostly 
SSRIs (n = 14; most often citalopram, n = 7). Only 16% of the 
total population of AD patients was on AD monotherapy. The 
difference was significant (see Figure 2). Furthermore, the part 
of combinations of AD with tranquillizer (benzodiazepines) 
without any other psychotropic drugs was higher in the 
ADR group (13% and 6%, respectively). In contrast, the com-
bination of AD with antipsychotics (APs) was seen less 
often in the ADR group (12% vs 22%). Polypharmacy, that is, 
combinations of ADs with more than one additional group 
of psychotropic drugs, was also lower in the ADR patients 
(33% vs 47%).
These results were in accordance with the findings of a case/
noncase analysis comparing the 83 cases of suicidal ADRs with 
4294 cases of nonsuicidal ADRs in AD treated patients (“non-
cases”, see supplementary Material). The reported odds ratios 
(ROR) concerning the occurrence of suicidal ADRs were sig-
nificantly higher than 1 in the ADR group for AD monotherapy 
(ROR = 2.9; CI1.80–4.60) and for the combination of AD plus TR 
(ROR = 2.7; CI 1.41–5.16) and significantly lower than 1 for AD 
plus APs (ROR = 0.4; CI 0.20–0.77) as well as for polypharmacy 
(i.e., AD plus more than one additional group of psychotropic 
drugs; ROR = 0.6; CI 0.36–0.91; see supplementary Table  1). The 
time-to-onset of ADR was not significant different for suicidal 
and nonsuicidal ADRs (median: 8.5 days vs 9 days in noncases, 
see supplementary Material; supplementary Table  2; supple-
mentary Figure 2).
Discussion
The results show that suicidal ADRs, that is, suicidal idea-
tions, suicide attempts, and fatal suicides, can occur in patients 
treated with ADs, but these events are rare. Restlessness and 
ego-dystonic thoughts or urges were the most frequently 
observed clinical features accompanying the ADRs, followed 
by impulsiveness. SSRIs were responsible for the highest rates 
of these ADRs, whereas TCAs and NaSSAs were imputed very 
rarely. Monotherapy with one AD was significantly more com-
mon in ADR patients, whereas combinations of ADs and APs as 
well as polypharmacy were less frequently administered in ADR 
patients than in all AD patients.
Overall, from 1993 to 2014 in the AMSP project, suicidal ADRs 
were assessed in 83 of 219,635 patients treated with ADs. This 
is equivalent to an incidence rate of 0.04% (in detail: 44 cases 
Table 1. Demographic Characteristics of Patients Who Developed Suicidal ADRs in Comparison with All Patients on Antidepressant Treatment 
under Surveillance of the AMSP Project
Patients with 
Antidepressant 
Treatment
Patients with 
Suicidal ADRs
Characteristic n % n % Significance Tests (ML-χ2)
219,635 100 83 100
Age [years] χ2 = 10.79, P = .005
 <30 29,359 13.4 18 21.7(+)
 30–60 124,939 56.9 52 62.6
 >60 65,337 29.7 13 15.7(-)
Gender χ2 = 1.15
 Male 82,605 37.6 36 43.4 P = .28
 Female 137,030 62.4 47 56.6
Main diagnosis according to ICD10 χ2 = 12.62 P = .013
 F1 9,486 4.3 2 2.4
 F2 28,889 13.2 4 4.8(-)
 F3 128,930 58.7 58 69.9(+)
 F4 and F6 32,808 14.9 16 19.3
 Other 19,522 8.9 3 3.6
Abbreviations: ADR, adverse drug reactions; AMSP, Arzneimittelsicherheit in der Psychiatrie; ICD-10, International Classification of Diseases, Tenth Revision; ML-χ2, 
maximum-likelihood chi-square tests.
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of suicidal ideation, 34 attempted suicides, and 5 committed 
suicides). This finding does not agree with certain epidemio-
logical data showing a higher percentage of suicidal ideation, 
as outlined by Baldessarini (2011). The apparent discrepancy is 
probably mainly due to different methodological approaches. 
Thus, in our study “cases” are recorded only when suicidal 
ideation or behavior is judged to be related to a particular anti-
depressant medication and additional symptoms allowing such 
a judgement are present (see Stübner et al., 2011).
In the period between 2009 and 2014, we found suicidal idea-
tion and suicidal behavior to be an ADR in 0.065% of AD patients 
(50 cases of 77,545 AD patients); in the previously analyzed 
period between 1993 and 2008, they occurred in 0.023% (Stübner 
et al., 2010). This increase may be attributed to the ascending 
use of SSRIs and a greater awareness within the AMSP surveil-
lance project resulting from our earlier report on suicidality as a 
rare ADR of ADs (Stübner et al., 2010).
It is important to note that the suicidal ADRs occurred within 
the first week (in 71% of the cases) or the first 2 weeks (93%) 
after onset or dosage increase of the imputed AD. This indicates 
that attention should be paid to possible suicidal ideation and 
behavior especially at the beginning of AD therapy. Our findings 
are in agreement with the data of Coupland and colleagues, who 
reported increased rates of suicides and attempted suicides or 
self-harm by persons with depression in the first 28  days of 
starting or stopping antidepressants; they also emphasized the 
need for careful monitoring of patients during these periods 
(Coupland et al., 2015).
Other factors might be correlated with an increased risk 
of developing suicidal ideation or behavior. However, we were 
unable to make a systematic analysis to identify such possible 
factors using our database.
Table 2. Data on Drug Use under Surveillance of the AMSP and Number of ADRs Observed between 1993 and 2014
Patients with 
Antidepressant Treatment
Patients with  
Suicidal ADRs*
Fisher’s Exact 
Test**
Antidepressant Subgroup  
or Substance n % n % P
All ADs 219,635a 100 83b 100
MAOIs 4421 2.0 2 2.3 .68
NaSSAs 56,910 25.9 8 9.6 .0004
SNRIs 49,216 22.4 16 19.3 .60
SSRIs 83,457 38.0 47 56.6 .0006
TCAs 52,442 23,9 3 3.6 .000001
OADs 19,705 9.0 11 13.25 .18
Moclobemide 2294 1.0 2 2.4
Mirtazapine 54,122 24.6 8 9.6 .0008
Duloxetine 12,059 5.5 3 3.6 .63
Venlafaxine 36,655 16.7 13 15.7 .88
Citalopram 23,664 10,8 22 26.5 .00005
Escitalopram 22,645 10.3 5 6.0 .28
Fluoxetine 5376 2.4 4 4.8 .15
Fluvoxamine 4078 1.9 2 2.4 .67
Paroxetine 9.988 4.5 5 6.0 .43
Sertraline 17,913 8.2 9 10.8 .32
Amitriptyline 13,405 6.1 3 3.6 .49
Agomelatine 3242 1.5 3 3.6
Bupropione 3385 1.5 4 4.8
Reboxetine 3266 1.5 1 1.2
Tianeptine 112 0.1 1 1.2
Trazodone 9797 4.5 2 2.4 .59
Abbreviations: AD, antidepressant; ADR, adverse drug reaction; AMSP, Arzneimittelsicherheit in der Psychiatrie; MAOI, monoamine oxidase inhibitor; NaSSA, noradr-
energic and specific serotonergic antidepressant; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, serotonin reuptake inhibitor; TCA, tricyclic antidepressant; 
OAD, other antidepressant.
* Imputed drugs for suicidal ADRs.
** Descriptive Fisher’s exact tests were performed if at least 4000 patients were monitored while on a drug.
a Treatment with more than one antidepressant possible.
b In 4 cases, 2 antidepressants were considered to have caused the ADR.
Figure  1. Incidences (diamonds) and exact asymmetric Cis (diamond with 
lines) for suicidal ADRs related to subgroups of antidepressant drugs (cases in 
which only a single antidepressant (AD) was assumed to cause the ADR; n = 71). 
Serotonin reuptake inhibitors (SSRIs), n = 40: incidence 0.05%; 95% CI between 
0.034 and 0.07; serotonin norepinephrine reuptake inhibitors (SNRIs), n = 14: 0.03% 
[95% CI, 0.016–0.05]; monoamine oxidase inhibitors (MAOIs), n = 2: 0.05% [95% CI, 
0.005–0.16]; noradrenergic and specific serotonergic antidepressants (NaSSAs), 
n = 6: 0.01% [95% CI, 0.004–0.02]; tricyclic antidepressants (TCAs), n = 2: 0.00% [95% 
CI, 0.000–0.01]; other antidepressants (OADs), n = 7: 0.04 [95% CI, 0.014.–0.07].
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Three clinical features could be identified as possible warning 
signs of emerging drug-induced suicidal ideation or suicidal behav-
ior: restlessness, ego-dystonic thoughts or urges, and increased 
impulsiveness. These symptoms are similar to the “activation 
syndrome” as described by the Food and Drug Administration as 
a risk factor of suicidal ADR induced by ADs in some patients. The 
syndrome includes anxiety, agitation, panic attacks, insomnia, 
irritability, hostility, impulsivity, akathisia (severe restlessness), 
hypomania, and mania (Culpepper et al., 2004).
Restlessness was the most frequent clinical feature during 
the entire period from 1993 to 2014 (52%). Motor restlessness 
resembles akathisia, which has been considered a risk factor for 
attempting suicide (Teicher et al., 1990; Arzneimittelkommission 
der deutschen Ärzteschaft, 2004; Seemüller et  al., 2009). SSRIs 
and other antidepressants have been reported to possibly trig-
ger akathisia, thus increasing vulnerability to eventually fatal 
suicidal (Healy et al., 1999).
Ego-dystonic thoughts or urges, that is, suicidal thoughts or 
behavior appearing strange to the inflicted patients themselves, 
were assessed in 47% of the patients with suicidal ADRs. It seems 
to be a rather specific clinical feature preceding suicidal ADRs. 
It shows similarities with obsessions in obsessive-compulsive 
disorders, which are usually treated with SSRIs. This raises the 
question of a possible paradoxical effect. Compared with our 
analysis of a smaller dataset earlier (Stübner et  al., 2010), the 
present study registered ego-dystonic thoughts or urges more 
often. This effect might be explained by a greater awareness of 
this phenomenon as a consequence of our first study.
Increased impulsiveness—observed in 27% of our ADR 
patients–was first reported for fluoxetine (Teicher et  al., 1990; 
Gualtieri, 1991) and subsequently also for other SSRIs (for review, 
see Healy et al., 1999). Since SSRIs are also administered to treat 
disorders with deficits of impulse control, this again raises 
the issue of a paradoxical effect. Similarly, an enhancement 
(Gelman and Atrio, 2017) and egodystonic disinhibition of libido 
have been observed in single patients on SSRIs (Greil et al., 2001), 
although loss of libido is considered a common adverse effect.
We observed suicidal ADRs mainly in patients on SSRIs (in 
57% of our cases, most often citalopram). The involvement of 
serotonergic medication (SSRIs and SNRIs in 76% of cases) and 
the clinical features described (impulsiveness, inner and motor 
restlessness) may indicate an involvement of serotonergic mech-
anisms in triggering suicidal ADRs (Meyer et al., 2003). In contrast, 
the NaSSA mirtazapine was associated with a distinctly lower 
incidence of suicidal ADRs (in 10% of the ADR cases) in accord-
ance with a pooled meta-analysis of the placebo control stud-
ies with mirtazapine (Kasper et al., 2010) as well as TCAs, which 
were involved in only 3.6% of suicidal ADRs. On the other hand, 
mirtazapine showed a propensity to trigger suicide attempts or 
self-harm in a large epidemiological study (Coupland et al., 2015).
Monotherapy (i.e., one AD without any psychotropic come-
dication) was more often found in the ADR group than in all AD 
patients as already described in our previous analysis (Stübner 
et  al., 2010). Polypharmacotherapy is commonly considered a 
risk factor for ADRs, but it is often required in clinically severe 
cases. The ADs applied in monotherapy in our study were usu-
ally SSRIs (mainly citalopram) and SNRIs. These drugs in particu-
lar may increase the risk of suicidal ADRs when given without 
sedative comedications (note, 2 cases of monotherapy were with 
the NaSSA mirtazapine).
Courtet and López-Castroman (2017) proposed further inves-
tigation of the combination of antipsychotics with antidepres-
sants regarding suicidal adverse reactions. In our study, AD and AP 
combination as well as polypharmacy are related to a lower inci-
dence in ADR patients compared with the total group of patients 
treated with ADs. One could speculate that this difference might 
indicate that this combination has a suicide-preventing effect, 
possibly due to the sedative effects of the antipsychotics applied 
as comedication (usually quetiapine, olanzapine, and prometh-
azine) and/or a serotonin antagonistic effect. An argument for 
the latter could be the fact that benzodiazepines seem to be not 
protective according to the results of this study.
The overall frequency of comedication of ADs with benzo-
diazepines (without any other psychotropic drugs) was higher 
in ADR patients than in all patients treated with ADs. However, 
benzodiazepines were used in almost one-half of the ADR 
patients (41%) to counteract the suicidal ADRs.
Comparing the 83 cases of suicidal ADRs with the cases 
of nonsuicidal ADRs in AD-treated patients in a case control 
analysis, these results could be confirmed (see supplemen-
tary Material). The ROR were significantly higher than 1 for 
AD monotherapy and for AD-TR combinations and lower for 
AD-AP combinations and for polypharmacy. Since underreport-
ing is present in reporting of all ADRs, the influence of under-
reporting on the results may be reduced using this approach. 
Monotherapy of AD may be more frequent in the beginning of 
hospitalization. The time to onset of suicidal and nonsuicidal 
ADRs being similar indicates that the apparent “pro-suicidal” 
effect of AD monotherapy (McElroy et al., 2006; Mihanović et al., 
2010) seems to be independent of the time to onset of suicidal 
ADRs, which is usually within 2 weeks.
The results have to be interpreted with the AMSP method 
and its strengths and limitations in mind (see also Stübner et al., 
2010). The advantage of the surveillance system is that the single 
cases of ADRs can be analyzed very precisely. This allows assess-
ment of all factors contributing to ADRs. Furthermore, the drugs 
applied in the observed ADRs can be related to the use of drugs in 
the centers participating in the AMSP project. A general limitation 
of the method, however, is that ADRs are often underreported. 
Another general problem is selective reporting of ADRs, especially 
when newer substances are involved. In this particular analysis, 
it should be noted that with regard to mental symptoms (as sui-
cidal thoughts or behavior), it remains difficult to distinguish 
Figure 2. Mono- and combination treatments in percent of all patients with anti-
depressant treatment monitored by Arzneimittelsicherheit in der Psychiatrie 
(AMSP; in blue, left bars) and in percent of all patients with suicidal adverse drug 
reactions (ADRs; in red, right bars), with CIs. AC, anticonvulsant; AP, antipsy-
chotic drug; TR, tranquillizer.
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between drug-related and illness-related events, even when all 
care is taken for the evaluation. Since the medication was not 
randomly assigned in this drug safety program in clinical routine, 
the choice of a particular antidepressant by the attending physi-
cian could have an impact. It might be that some antidepressants, 
for example, SSRIs, were preferred in patients prone to suicidality 
due to low toxicity. This bias cannot be ruled out. More accurate 
information could be gained in future research by case control 
designs that include no treatment and other treatment groups. In 
this study, we additionally applied a special form of case control 
design, the case/noncase approach, to confirm the results with 
another method (see supplementary Material). Finally, the public 
debate on suicidality during treatment with SSRIs (Baldessarini 
et al., 2017; Courtet and López-Castroman, 2017; Silverman, 2017) 
might have influenced the general awareness and led to selective 
observation and reporting in more recent years.
Conclusions
Our analysis of the large dataset of AMSP supports the view that 
suicidal ADRs can be triggered by AD treatment (primarily SSRIs) 
in rare cases. The results obtained previously are supported by 
the now larger database. Restlessness, ego-dystonic thoughts or 
urges, and impulsiveness are important clinical characteristics 
of patients who developed suicidal ideation or behavior as ADRs 
and may be considered possible warning signs. Especially in the 
first 2 weeks of antidepressant medication, special attention 
should be paid to these patients.
As regards suicidal thoughts or behavior as ADR, the results 
could indicate that a combination therapy might be preferable 
to AD monotherapy when beginning treatment. In particular, a 
co-medication with antipsychotics might be helpful to avoid the 
onset of suicidal ADRs. According to the present study, the very 
low risk of the AD-induced ADR of suicidal ideation and behav-
ior does not seem to be reduced effectively by the combination 
of ADs with benzodiazepines alone, that is, without any other 
psychotropic drugs.
Supplementary Materials
Supplementary data are available at The International Journal of 
Neuropsychopharmacology online.
Acknowledgments
We thank all the cooperating hospitals and their staff for their 
contribution to data collection. We are also grateful to Judy 
Benson for copyediting the manuscript.
Statement of Interest
The AMSP Drug Safety Program is organized by nonprofit asso-
ciations in Germany, Austria, and Switzerland. Almost all phar-
maceutical companies involved in CNS research contribute 
financial support to the 3 associations.
Educational and research grants since 1993
Austrian companies: Astra Zeneca Österreich GmbH, 
Boehringer Ingelheim Austria, Bristol Myers Squibb GmbH, 
CSC Pharmaceuticals GmbH, Eli Lilly GmbH, Germania Pharma 
GmbH, GlaxoSmithKline Pharma GmbH, Janssen-Cilag Pharma 
GmbH, Lundbeck GmbH, Novartis Pharma GmbH, Pfizer Med 
Inform, and Wyeth Lederle Pharma GmbH.
German companies: Abbott GmbH & Co. KG, AstraZeneca 
GmbH, Aventis Pharma Deutschland GmbH GE-O/R/N, Bayer Vital 
GmbH & Co. KG, Boehringer Mannheim GmbH, Bristol-Myers-
Squibb, Ciba Geigy GmbH, Desitin Arzneimittel GmbH, Duphar 
Pharma GmbH & Co. KG, Eisai GmbH, esparma GmbH Arzneimittel, 
GlaxoSmithKline Pharma GmbH & Co. KG, Hoffmann-La Roche AG 
Medical Affairs, Janssen-Cilag GmbH, Janssen Research Foundation, 
Knoll Deutschland GmbH, Lilly Deutschland GmbH Niederlassung 
Bad Homburg, Lundbeck GmbH & Co. KG, Novartis Pharma GmbH, 
Nordmark Arzneimittel GmbH, Organon GmbH, Otsuka-Pharma 
Frankfurt, Pfizer GmbH, Pharmacia & Upjohn GmbH, Promonta 
Lundbeck Arzneimittel, Rhone-Poulenc Rohrer, Sanofi-Synthelabo 
GmbH, Sanofi-Aventis Deutschland, Schering AG, SmithKline 
Beecham Pharma GmbH, Solvay Arzneimittel GmbH, Synthelabo 
Arzneimittel GmbH, Dr. Wilmar Schwabe GmbH & Co., Thiemann 
Arzneimittel GmbH, Troponwerke GmbH & Co. KG, Upjohn GmbH, 
Wander Pharma GmbH, and Wyeth-Pharma GmbH.
Switzerland companies: AHP (Schweiz) AG, AstraZeneca AG, 
Bristol-Myers Squibb AG, Desitin Pharma GmbH, Eli Lilly (Suisse) 
S.A., Essex Chemie AG, GlaxoSmithKline AG, Janssen-Cilag 
AG, Lundbeck (Suisse) AG, Organon AG, Pfizer AG, Pharmacia, 
Sanofi-Aventis (Suisse) S.A., Sanofi-Synthélabo SA, Servier SA, 
SmithKlineBeecham AG, Solvay Pharma AG, Wyeth AHP (Suisse) 
AG, and Wyeth Pharmaceuticals AG.
R. Grohmann is a project manager of AMSP. S. Kasper received 
grants/research support, consulting fees, and/or honoraria over 
the last 3  years from Angelini, AOP Orphan Pharmaceuticals 
AG, AstraZeneca, Eli Lilly, Janssen, KRKA-Pharma, Lundbeck, 
Neuraxpharm, Pfizer, Pierre Fabre, Schwabe, and Servier. H.-J. 
Möller received in the last 3 years honoraria for lectures or expert 
meetings by the following pharmaceutical companies: Lundbeck, 
Schwabe, Otsuka, and Servier. He was president or on the exec-
utive board of the following organizations: CINP, ECNP, WFSBP, 
EPA, and chairman of the WPA-section on Pharmacopsychiatry. 
E.  Rüther has received research grants from Lilly, Lundbeck, 
BMS, Astra-Zeneca, and Bayer and is a consultant for and on the 
speakership bureaus of Servier, Otsouka, Lundbeck, Wyeth, and 
Lilly. S. Toto is a project manager of AMSP, has been a member of 
an advisory board for Otsouka, and has received speaker´s hono-
raria from Janssen Cilag, Lundbeck, Otsouka, and Servier.
All other authors have no conflicts of interest to be declared.
References
Arzneimittelkommission der deutschen Ärzteschaft (2004) SSRI 
und Suizidalität? Deutsches Ärzteblatt 101:A2642.
Baldessarini RJ (2011) Suicidal risk during antidepressant treat-
ment. J Clin Psychiatry 72:722; author reply 722.
Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K (2017) Suicidal risks 
in reports of long-term controlled trials of antidepressants 
for major depressive disorder II. Int J Neuropsychopharmacol 
20:281–284.
Braun C, Bschor T, Franklin J, Baethge C (2016) Suicides and 
suicide attempts during long-term treatment with antide-
pressants: a meta-analysis of 29 placebo-controlled stud-
ies including 6,934 patients with major depressive disorder. 
Psychother Psychosom 85:171–179.
Brent DA (2016) Antidepressants and suicidality. Psychiatr Clin 
North Am 39:503–512.
Clopper C, Pearson ES (1934) The use of confidence of fiducial 
limits illustrated in the case of the binominal. Biometrika 
26:404–413.
Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J 
(2015) Antidepressant use and risk of suicide and attempted 
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/21/9/814/5043110 by guest on 21 N
ovem
ber 2019
Stübner et al. | 821
suicide or self harm in people aged 20 to 64: cohort study 
using a primary care database. Bmj 350:h517.
Courtet P, Lopez-Castroman J (2017) Antidepressants and suicide 
risk in depression. World Psychiatry 16:317–318.
Culpepper L, Davidson JR, Dietrich AJ, Goodman WK, Kroenke K, 
Schwenk TL (2004) Suicidality as a possible side effect of anti-
depressant treatment. J Clin Psychiatry 65:742–749.
Damluji NF, Ferguson JM (1988) Paradoxical worsening of depres-
sive symptomatology caused by antidepressants. J Clin 
Psychopharmacol 8:347–349.
Engel RR, Grohmann R, Rüther E, Hippius H (2004) Research meth-
ods in drug surveillance. Pharmacopsychiatry 37:S12–S15.
Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert 
P, Hutton B (2005) Association between suicide attempts and 
selective serotonin reuptake inhibitors: systematic review of 
randomised controlled trials. Bmj 330:396.
Gelman F, Atrio J (2017) Flibanserin for hypoactive sexual desire 
disorder: place in therapy. Ther Adv Chronic Dis 8:16–25.
Greil W, Horvath A, Sassim N, Erazo N, Grohmann R (2001) 
Disinhibition of libido: an adverse effect of SSRI? J Affect 
Disord 62:225–228.
Grohmann R, Ströbel C, Rüther E, Dirschedl P, Helmchen H, 
Hippius H, Müller-Oerlinghausen B, Schmidt LG, Wolf B (1993) 
Adverse psychic reactions to psychotropic drugs–a report 
from the AMUP study. Pharmacopsychiatry 26:84–93.
Grohmann R, Engel RR, Rüther E, Hippius H (2004) The 
AMSP drug safety program: methods and global results. 
Pharmacopsychiatry 37:12–15.
Grohmann R, Engel RR, Möller HJ, Rüther E, van der Velden JW, 
Stübner S (2014) Flupentixol use and adverse reactions in 
comparison with other common first- and second-gener-
ation antipsychotics: data from the AMSP study. Eur Arch 
Psychiatry Clin Neurosci 264:131–141.
Gualtieri CT (1991) Paradoxical effects of fluoxetine. J Clin 
Psychopharmacol 11:393–394.
Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake 
inhibitors (ssris) and suicide in adults: meta-analysis of drug 
company data from placebo controlled, randomised con-
trolled trials submitted to the MHRA’S safety review. Bmj 
330:385.
Healy D, Langmaak C, Savage M (1999) Suicide in the course of 
the treatment of depression. J Psychopharmacol 13:94–99.
Healy D, Whitaker C (2003) Antidepressants and suicide: risk-
benefit conundrums. J Psychiatry Neurosci 28:331–337.
Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA (2006) The 
risk of suicide with selective serotonin reuptake inhibitors in 
the elderly. Am J Psychiatry 163:813–821.
Kasper S, Montgomery SA, Möller HJ, van Oers HJJ, Schutte AJ, 
Vrijland P, Van der Meulen EA (2010) Longitudinal analysis of 
the suicidal behaviour risk in short-term placebo-controlled 
studies of mirtazapine in major depressive disorder. World J 
Biol Psychiatry 11:36–44.
Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, 
Evans S, Gunnell D (2005) Antidepressant treatment and the 
risk of fatal and non-fatal self harm in first episode depres-
sion: nested case-control study. Bmj 330:389.
McElroy SL, Kotwal R, Kaneria R, Keck PE Jr (2006) Antidepressants 
and suicidal behavior in bipolar disorder. Bipolar Disord 
8:596–617.
Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, 
DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, 
Houle S, Links P (2003) Dysfunctional attitudes and 5-HT2 
receptors during depression and self-harm. Am J Psychiatry 
160:90–99.
Mihanović M, Restek-Petrović B, Bodor D, Molnar S, Oresković A, 
Presecki P (2010) Suicidality and side effects of antidepres-
sants and antipsychotics. Psychiatr Danub 22:79–84.
Möller HJ (2006) Is there evidence for negative effects of antide-
pressants on suicidality in depressive patients? A systematic 
review. Eur Arch Psychiatry Clin Neurosci 256:476–496.
Möller HJ, Baldwin DS, Goodwin G, Kasper S, Okasha A, Stein DJ, 
Tandon R, Versiani M, WPA Section on Pharmacopsychiatry 
(2008) Do SSRIs or antidepressants in general increase sui-
cidality? WPA section on pharmacopsychiatry: consensus 
statement. Eur Arch Psychiatry Clin Neurosci 258:3–23.
Rouillon F, Phillips R, Serrurier D, Ansart E, Gérard MJ (1989) 
Recurrence of unipolar depression and efficacy of mapro-
tiline. Encephale 15:527–534.
Seemüller F, Riedel M, Obermeier M, Bauer M, Adli M, Mundt 
C, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler 
J, Gaebel W, Jäger M, Henkel V, Möller HJ (2009) The contro-
versial link between antidepressants and suicidality risks 
in adults: data from a naturalistic study on a large sam-
ple of in-patients with a major depressive episode. Int J 
Neuropsychopharmacol 12:181–189.
Silverman E (2017) US drug regulators should consider add-
ing adults to SSRI suicide warning, says campaigner. Bmj 
357:j2050.
Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes 
A, Hammad TA, Temple R, Rochester G (2009) Risk of suicidal-
ity in clinical trials of antidepressants in adults: analysis of 
proprietary data submitted to US food and drug administra-
tion. Bmj 339:b2880.
Ströbel C, Grohmann R, Rüther E, Schmidt LG (1994) Stationäre 
UAW-Erfassung: Antidepressiva. In: Unerwünschte 
Wirkungen von Psychopharmaka: Ergebnisse der AMÜP-
Studie (Grohmann R, Rüther E, Schmidt LG, eds), pp 134–204. 
Berlin: Springer.
Stübner S, Grohmann R, von Stralendorff I, Rüther E, Möller HJ, 
Müller-Oerlinghausen B, Engel RR, Horvath A, Greil W (2010) 
Suicidality as rare adverse event of antidepressant medica-
tion: report from the AMSP multicenter drug safety surveil-
lance project. J Clin Psychiatry 71:1293–1307.
Stübner S, Grohmann R, Greil W (2011) Dr Stübner and col-
leagues reply. J Clin Psychiatry 72:722.
Teicher MH, Glod C, Cole JO (1990) Emergence of intense suicidal 
preoccupation during fluoxetine treatment. Am J Psychiatry 
147:207–210.
Vanderburg DG, Batzar E, Fogel I, Kremer CM (2009) A pooled 
analysis of suicidality in double-blind, placebo-controlled 
studies of sertraline in adults. J Clin Psychiatry 70:674–683.
Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, 
Boddington E (2004) Selective serotonin reuptake inhibitors 
in childhood depression: systematic review of published ver-
sus unpublished data. Lancet 363:1341–1345.
Whittington CJ, Kendall T, Pilling S (2005) Are the SSRIs and atyp-
ical antidepressants safe and effective for children and ado-
lescents? Curr Opin Psychiatry 18:21–25.
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/21/9/814/5043110 by guest on 21 N
ovem
ber 2019
